Harmonia Mentis Norway
Bernhard Steinhoff: The distinctive pharmacological and clinical profile of cenobamate
"Time is brain" – learn how early seizure control, timely surgery, and treatment strategies impact morbidity, mortality, and long-term outcomes in epilepsy.
Introduction
Despite of considerable scientific progress in development of anti-seizure treatments the challenge of achieving seizure-freedom remains1,2. Understanding the available treatments and how they address current treatment gaps may help in improving treatment outcomes. In this lecture Dr. Steinhoff describes cenobamate’s known mechanisms of action, its pharmacological profile and talks about a selection of clinical studies.
Dr. Bernhard Steinhoff (MD, PhD) is professor of neurology and clinical neurophysiology at University of Freiburg and medical director in the Kork Epilepsy Center, Kehl-Kork, Germany
This slide deck was presented by Dr. Bernhard Steinhoff at the "From Now On" meeting 28.11.2023. The meeting was arranged and funded by Angelini Pharma S.p.a. The opinions expressed in the slides are solely those of the presenter and not necessarily those of Angelini Pharma. Angelini Pharma does not guarantee the accuracy or reliability of the information herein.
- Chen Z, Brodie MJ, Liew D et al. Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs. JAMA Neurol. 2018 Mar; 75(3): 279–2862018
- Kwan P, Brodie MJ. Early Identification of Refractory Epilepsy. N Engl J Med 2000;342:314-319
MAT-NO-0043-P 2.12.2025